Publications by authors named "R D Plattner"

Claim this Profile
A
ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization.
Anastasia Lyon, Rakshamani Tripathi, Christina Meeks, Daheng He, Yuanyuan Wu, Rina Plattner

Cancers (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of ABL1 by tyrosine kinase inhibitors leads to a downregulation of MLH1 by Hsp70-mediated lysosomal protein degradation.
Hannah G Daniels, Breanna G Knicely, Anna Kristin Miller, Ana Thompson, Rina Plattner

Front Genet· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer.
Kristen S Hill, Anthony McDowell, J Robert McCorkle, Erin Schuler, Sally R Ellingson, Rina Plattner

Cancers (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling.
Rakshamani Tripathi, Zulong Liu, Aditi Jain, Anastasia Lyon, Christina Meeks, Rina Plattner

Nat Commun· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EnABLing Tumor Growth and Progression: Recent progress in unraveling the functions of ABL kinases in solid tumor cells.
Rakshamani Tripathi, Zulong Liu, Rina Plattner

Curr Pharmacol Rep· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis